MorphoSys AG

NasdaqGS:MOR 株式レポート

時価総額:US$2.8b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

MorphoSys 過去の業績

過去 基準チェック /06

MorphoSys's earnings have been declining at an average annual rate of -27.6%, while the Biotechs industry saw earnings growing at 16.1% annually. Revenues have been growing at an average rate of 11% per year.

主要情報

-27.6%

収益成長率

-26.8%

EPS成長率

Biotechs 業界の成長17.0%
収益成長率11.0%
株主資本利益率n/a
ネット・マージン-194.0%
次回の業績アップデート07 Aug 2024

最近の業績更新

Recent updates

MorphoSys: Hold Rating Until The Novartis Deal Closes

May 01

Novartis And MorphoSys Are A Perfect Match

Feb 06

MorphoSys: Positive Pelabresib Data Finally Unlocking Upside

Jan 18

MorphoSys updates Q2 & FY22 guidance below prior provided levels

Jul 26

MorphoSys May Not Recover From Adventurous Constellation Buyout

May 04

Sierra Oncology's Strong Data In Myelofibrosis Challenges MorphoSys And Incyte

Jan 28

Incyte and MorphoSys presents new three-year data for blood cancer therapy

Jun 04

MorphoSys reports Q1 results

May 05

MorphoSys AG appoints Sangamo 's Sung Lee as new CFO

Jan 06

MorphoSys AG (MOR) Investor Presentation - Slideshow

Dec 08

MorphoSys AG 2020 Q3 - Results - Earnings Call Presentation

Nov 22

MorphoSys reports Q3 results

Nov 11

収支内訳

MorphoSys の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqGS:MOR 収益、費用、利益 ( )EUR Millions
日付収益収益G+A経費研究開発費
31 Mar 24241-469337294
31 Dec 23238-190147274
30 Sep 23223104128271
30 Jun 23255100133286
31 Mar 23261-61130290
31 Dec 22278-151153290
30 Sep 22250-861143289
30 Jun 22195-851156276
31 Mar 22174-596178255
31 Dec 21180-514180224
30 Sep 21163-150196191
30 Jun 21143-103191160
31 Mar 21124-177175151
31 Dec 2032898159125
30 Sep 2030364140104
30 Jun 2029310510796
31 Mar 203091537590
31 Dec 1972-10359107
30 Sep 1971-9642101
30 Jun 19114-423594
31 Mar 1987-593195
31 Dec 1876-562887
30 Sep 1894-272585
30 Jun 1854-8223101
31 Mar 1858-742198
31 Dec 1767-7021103
30 Sep 1752-8417106
30 Jun 1749-731694
31 Mar 1749-681590
31 Dec 1650-601684
30 Sep 1649-451581
30 Jun 1648-401578
31 Mar 1648-331579
31 Dec 15106151575
30 Sep 15111271464
30 Jun 15116331462
31 Mar 15119371455
31 Dec 1464-31452
30 Sep 1461-61653
30 Jun 1460-51748
31 Mar 147771848
31 Dec 137871848
30 Sep 1380141744

質の高い収益: MOR is currently unprofitable.

利益率の向上: MOR is currently unprofitable.


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: MOR is unprofitable, and losses have increased over the past 5 years at a rate of 27.6% per year.

成長の加速: Unable to compare MOR's earnings growth over the past year to its 5-year average as it is currently unprofitable

収益対業界: MOR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-34.5%).


株主資本利益率

高いROE: MOR's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


総資産利益率


使用総資本利益率


過去の好業績企業の発掘